GSK’s respiratory syncytial virus older adult vaccine candidate granted Priority Review by US FDA

GSK delivers strong Q3 2022 sales of £7.8 billion +18% AER, +9% CER and Total EPS 255.9p +>100% AER, +>100% CER; Adjusted EPS of 46.9p +25% AER, +11% CER


European Medicines Agency validates ViiV Healthcare’s marketing authorisation application for cabotegravir long-acting injectable for HIV Prevention


GSK marketing authorisation application for respiratory syncytial virus older adult vaccine candidate accepted by European Medicines Agency under accelerated assessment


GSK provides update on ContRAst phase III programme for otilimab in the treatment of moderate to severe rheumatoid arthritis


GSK reports outcome from US FDA Advisory Committee meeting on daprodustat for anaemia of CKD